LONDON — GlaxoSmithKline PLC said Monday it had reached a deal with Indian drug developer Dr. Reddy’s Laboratories Ltd. to develop and market selected products across many emerging markets.
London-based Glaxo did not reveal terms of the deal, which is effective immediately but excludes India.
Under the agreement, Glaxo will gain exclusive access to Dr. Reddy’s portfolio and future pipeline of more than 100 branded pharmaceuticals in fast growing therapeutic segments such as cardiovascular, diabetes, oncology, gastroenterology and pain management.
http://www.pharmpro.com/ShowPR.aspx?PUBCODE=021&ACCT=0000100&ISSUE=0906&RELTYPE=IN&PRODCODE=0000&PRODLETT=DH&CommonCount=0
Gerard says:
July 2015
Blogroll
Tag Bag
Tag Cloud
biotech Braille Branding business carbon compliance compostable cosmetic cosmetics cost-optimisation counterfeit Design drink environment ethical event food fun gift Government healthcare Innovation Legal Marketing material Materials music news packaging pharma PLM Recycling research Result Retailers skincare socialmedia sustainability Technology toiletries Training trend tweet waste WRAP
WP Cumulus Flash tag cloud by Roy Tanck requires Flash Player 9 or better.
Twitter Feed
Posting tweet...